Allergy:花粉季节新的EAACI定义能够反应草和桦树花粉诱导的过敏性鼻炎症状负荷

2018-05-29 AlexYang MedSci原创

过敏原免疫疗法(AIT)在过敏性鼻炎中的使用和它的临床试验效果依赖于花粉过敏原接触的时期的有效判断。最近,有研究人员评估了德国花粉数据资料,从而来调查对花粉季节和花粉峰值开始和结束时间的新的定义。研究人员的目的是依据现实生活数据来阐释这些定义反应草和桦树花粉诱导的过敏性鼻炎症状负荷的能力。研究人员利用来自德国柏林和勃兰登堡4个花粉检测地点的3年(2014-2016)的数据来进行季节定义、桦树和草花

过敏原免疫疗法(AIT)在过敏性鼻炎中的使用和它的临床试验效果依赖于花粉过敏原接触的时期的有效判断。最近,有研究人员评估了德国花粉数据资料,从而来调查对花粉季节和花粉峰值开始和结束时间的新的定义。研究人员的目的是依据现实生活数据来阐释这些定义反应草和桦树花粉诱导的过敏性鼻炎症状负荷的能力。

研究人员利用来自德国柏林和勃兰登堡4个花粉检测地点的3年(2014-2016)的数据来进行季节定义、桦树和草花粉数量和全部鼻症状以及药物得分相关性的调查。研究人员还在详细的图形调查后,进行了统计学分析。研究发现,EAACI提出的花粉季节的新的定义以及花粉峰值开始和结束时间与患者报道的草和桦树花粉诱导的过敏性鼻炎症状负荷具有相关关系。

最后,研究人员指出,基于他们的分析,EAACI定义对花粉季节的有效性是确定的。在以后的关于AIT的临床试验以及优化日常患者护理中,研究人员也推荐使用。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2046973, encodeId=510d20469e3f6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jan 27 09:48:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745132, encodeId=278d1e45132eb, content=<a href='/topic/show?id=08fe62398b5' target=_blank style='color:#2F92EE;'>#桦树花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62398, encryptionId=08fe62398b5, topicName=桦树花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun May 12 05:48:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329118, encodeId=fbb21329118c8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396421, encodeId=1fcd13964211b, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468687, encodeId=7a69146868e8d, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2046973, encodeId=510d20469e3f6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jan 27 09:48:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745132, encodeId=278d1e45132eb, content=<a href='/topic/show?id=08fe62398b5' target=_blank style='color:#2F92EE;'>#桦树花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62398, encryptionId=08fe62398b5, topicName=桦树花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun May 12 05:48:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329118, encodeId=fbb21329118c8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396421, encodeId=1fcd13964211b, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468687, encodeId=7a69146868e8d, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2046973, encodeId=510d20469e3f6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jan 27 09:48:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745132, encodeId=278d1e45132eb, content=<a href='/topic/show?id=08fe62398b5' target=_blank style='color:#2F92EE;'>#桦树花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62398, encryptionId=08fe62398b5, topicName=桦树花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun May 12 05:48:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329118, encodeId=fbb21329118c8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396421, encodeId=1fcd13964211b, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468687, encodeId=7a69146868e8d, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 膀胱癌
  4. [GetPortalCommentsPageByObjectIdResponse(id=2046973, encodeId=510d20469e3f6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jan 27 09:48:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745132, encodeId=278d1e45132eb, content=<a href='/topic/show?id=08fe62398b5' target=_blank style='color:#2F92EE;'>#桦树花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62398, encryptionId=08fe62398b5, topicName=桦树花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun May 12 05:48:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329118, encodeId=fbb21329118c8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396421, encodeId=1fcd13964211b, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468687, encodeId=7a69146868e8d, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2046973, encodeId=510d20469e3f6, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Sun Jan 27 09:48:00 CST 2019, time=2019-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745132, encodeId=278d1e45132eb, content=<a href='/topic/show?id=08fe62398b5' target=_blank style='color:#2F92EE;'>#桦树花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=62398, encryptionId=08fe62398b5, topicName=桦树花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sun May 12 05:48:00 CST 2019, time=2019-05-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329118, encodeId=fbb21329118c8, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1396421, encodeId=1fcd13964211b, content=<a href='/topic/show?id=89f18693e6e' target=_blank style='color:#2F92EE;'>#花粉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86937, encryptionId=89f18693e6e, topicName=花粉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=智者为医08, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1468687, encodeId=7a69146868e8d, content=<a href='/topic/show?id=a19b4540688' target=_blank style='color:#2F92EE;'>#季节#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45406, encryptionId=a19b4540688, topicName=季节)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cf986929326, createdName=30397606, createdTime=Thu May 31 09:48:00 CST 2018, time=2018-05-31, status=1, ipAttribution=)]
    2018-05-31 30397606

相关资讯

Int Immunopharmacol:过敏性鼻炎患者中,IL-1R8的表达增加且其配体IL-37具有免疫调节作用

过敏性鼻炎(AR)是一种慢性气道炎症性疾病,并且是由异常的T细胞响应引起。T辅助(Th)-17细胞和Th2细胞是 CD4+ T细胞的其中一部分,并且在AR的发病机理中有作用。这些Th17和Th2细胞过度响应的抑制在治疗AR患者中非常有效,并且正在研究其持续的效应,从而为调控这些细胞的功能找到新的方法。之前的研究表明了IL-1R8和它的配体IL-37能够负调控免疫响应。最近,有研究人员在AR患者中调

J Laryngol Otol:过敏性鼻炎与动脉血压关系研究

最近,有研究人员为了调查过敏性鼻炎和潜在并发症的可能性,以及评估是否过敏性鼻炎与动脉血压和高血压相关,进行了相关研究。在他们的基于群体的研究中,包括了369名过敏性鼻炎和哮喘成年人,并通过调查问卷和免疫球蛋白E水平进行相关评估。研究包括了4个小组:对照(n=90)、过敏性鼻炎(n=99)、哮喘(n=87)和高血压(n=93),并且在所有小组中测量了动脉血压。研究发现,在任一小组的男性和女性中,收缩

盘点:近期过敏性鼻炎免疫治疗研究进展一览

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】J Med Econ:草花粉皮下免疫疗法(SCIT)与

Eur Arch Otorhinolaryngol:过敏性鼻炎中IL-13和CD14基因单核苷酸多态性分析

最近,有研究人员进行了元分析,目的是研究白介素-13(IL-13)和分化群14(CD14)基因的单核苷酸多态性情况和过敏性鼻炎(AR)的风险情况。研究人员筛选了在7个数据库中的数据,包括了Pubmed、Medline、Web of Science、Embase、China Biology Medicine disc、 Wanfang和中国学术期刊网络出版数据库。研究人员利用让步比(ORs)和95%

J Allergy Clin Immunol Pract:成年人中轻度哮喘的长期发展轨迹和恶化风险因子分析

大多数哮喘患者的疾病程度较轻。然而,轻度哮喘的临床过程和恶化的风险因子却没有很详细的研究。最近,有研究人员调查了轻度哮喘的长期发展轨迹和早期风险因素对虽有疾病情况的影响。研究包括了在1997年到2012年被新诊断为轻度哮喘的年龄在14岁到45岁之间的患者。研究人员利用序数逻辑回归评估了相关参数之间的关系。研究共包括了70829名伴随轻度哮喘的患者(62%为女性,平均年龄为31岁)。在10年间,8%

盘点:近期过敏性鼻炎研究进展

过敏性鼻炎主要由IgE介导的介质(主要是组胺)释放,并有多种免疫活性细胞和细胞因子等参与的鼻黏膜非感染性炎性疾病。其发生的必要条件有特异性抗原即引起机体免疫反应的物质、特应性个体、特异性抗原与特应型个体二者相遇。过敏性鼻炎是一个全球性健康问题,可导致许多疾病和劳动力丧失。梅斯医学小编整理了近期过敏性鼻炎的研究进展,与大家一起分享学习!【1】Int J Pediatr Otorhinolaryn